GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Berry Genomics Co Ltd (SZSE:000710) » Definitions » EBIT

Berry Genomics Co (SZSE:000710) EBIT : ¥-343 Mil (TTM As of Sep. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Berry Genomics Co EBIT?

Berry Genomics Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥35 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥-343 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Berry Genomics Co's annualized ROC % for the quarter that ended in Sep. 2024 was 0.90%. Berry Genomics Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 11.03%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Berry Genomics Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -7.19%.


Berry Genomics Co EBIT Historical Data

The historical data trend for Berry Genomics Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Berry Genomics Co EBIT Chart

Berry Genomics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 445.76 260.68 -106.97 -258.74 -437.07

Berry Genomics Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.32 -405.76 16.59 10.62 35.30

Competitive Comparison of Berry Genomics Co's EBIT

For the Diagnostics & Research subindustry, Berry Genomics Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Berry Genomics Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Berry Genomics Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Berry Genomics Co's EV-to-EBIT falls into.


;
;

Berry Genomics Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-343 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Berry Genomics Co  (SZSE:000710) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Berry Genomics Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=54.784 * ( 1 - 65.77% )/( (2211.118 + 1938.176)/ 2 )
=18.7525632/2074.647
=0.90 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2902.618 - 387.493 - ( 304.007 - max(0, 955.27 - 1514.303+304.007))
=2211.118

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2539.381 - 359.272 - ( 241.933 - max(0, 591.762 - 1595.575+241.933))
=1938.176

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Berry Genomics Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=141.18/( ( (891.553 + max(397.916, 0)) + (408.313 + max(861.781, 0)) )/ 2 )
=141.18/( ( 1289.469 + 1270.094 )/ 2 )
=141.18/1279.7815
=11.03 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(882.739 + 204.03 + 111.37) - (387.493 + 0 + 412.73)
=397.916

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1064.986 + 193.549 + 82.905) - (359.272 + 0 + 120.387)
=861.781

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Berry Genomics Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-343.254/4770.967
=-7.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Berry Genomics Co EBIT Related Terms

Thank you for viewing the detailed overview of Berry Genomics Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Berry Genomics Co Business Description

Traded in Other Exchanges
N/A
Address
Life Park Road, Building 5, Courtyard 4, Science and Technology Park, Changping District, Beijing, CHN
Berry Genomics Co Ltd is a biotechnology company. It providess gene sequencing detection equipment and services.
Executives
Gao Yang Directors, executives
Hou Ying Directors, executives
Wang Yu Jing Supervisors
Wang Dong Directors, executives
Zhou Dai Xing Directors, executives
Ou Yang Xiang Yu Supervisors
Li Guang Chao Independent director
Gu Zhong Guo Directors, executives
Wen Wu Director
Ding Xian Xing Supervisors

Berry Genomics Co Headlines

No Headlines